Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Lumacaftor/Ivacaftor in Young Children with Cystic Fibrosis
NCT04235140Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2020
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of lumacaftor, ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Feb 2020; status: completed.
02
Drugs
lumacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04235140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04235140.